Christine M. Debouck, Ph.D.
Dr. Christine M. Debouck is President of Ardennes Biosciences LLC, a consulting company focusing on pharmaceutical research and biomarkers, and is renowned for her expertise in target validation, disease mechanisms and compound characterization in pre-clinical and clinical development, and biomarker evaluation with an emphasis in oncology and infectious diseases. Dr. Debouck advises a number of drug discovery companies and research funding entities, including the Bill & Melinda Gates Foundation, the Grand Challenges Canada initiative, and the European Commission.
Dr. Debouck was formerly Senior Vice President, Genomic & Proteomic Sciences, Genetics Research Division at GlaxoSmithKline, where she managed 200 research scientists working in a transnational setting and conducting cutting edge functional genomics. She assumed positions of increasing responsibility within the organization, beginning with her post-doctoral work in the former SmithKline & French Laboratories. While at SK&F, Dr. Debouck made significant contributions to the field of HIV and was the first to report on the identification of the HIV protease and its proteolytic activity. She led the AIDS Drug Discovery Program in SK&F and SmithKline Beecham before taking on the leadership of the company's genomics initiative. She also conducted post-doctoral work at the National Cancer Institute, working on the regulation of gene expression.
Dr. Debouck received her Bachelor's and Master's, degrees in Zoology-Molecular Biology, summa cum laude from the University of Brussels-Belgium, Department of Genetics. She also earned her PhD summa cum laude from the University of Brussels–Belgium, where she studied the regulation of prokaryotic transcription and translation. She has authored 116 publications and holds 17 issued patents.